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pretreatment with 5 μM NE in a concentration-dependent manner.
NG-monomethyl-l-arginine acetate (L-NMMA)(100 μM), a NO syn-
thesis inhibitor, reduced the quercetin (100 μM)-induced vasorelax-
ation from 97.0 ± 3.7% (n= 10, P b 0.05) to 78.0 ± 11.6% (n= 5,
P b 0.05). Endothelium removal as well attenuated the vasodilatation.
In the presence of both 100 μM L-NMMA and 10 μM indomethacin, the
quercetin-induced vasorelaxation was further attenuated by high K
(30 mM) or 10 μM tetraethylammonium (TEA, KCa channel inhibitor).
Nicardipine caused less or no effect on the relaxation. The quercetin-
induced vasodilatation was attenuated by 0.3 μM apamin (SK channel
inhibitor), but not by 30 nM charybdotoxin (BK and IK channel
blockers). Under KCl-induced vasoconstriction, the quercetin-induced
vasorelaxationwas attenuated by PK-C inhibitors. Gö6983 (α-, β-, γ-, δ-
and ζ-sensitive) produced a stronger relaxing effect than Ro-31-8425
(α-, β-, γ- and ε-sensitive). These results indicate that the vasorelax-
ation is dependent on the endothelium, and is also exerted by the
modulation of SK channel and PK-Cδ. In rat mesenteric artery, the
quercetin-induced vasodilatation was in part resistant to both
100 μM L-NG-nitro arginine methyl ester (L-NAME) and 100 μM
indomethacin. The L-NAME- and indomethacin-resistant quercetin-
induced vasodilatation was attenuated by TEA (1 mM) and also by
100 μM 18α- and 50 μM 18β-glychrrhetinic acids (gap junction
inhibitors). These results indicate that the vasorelaxation is also
dependent on the endothelium and KCa channel, and is further
produced by the modulation of the gap junction. Therefore, quercetin
vasodilates the vascular smooth muscle mediated by endothelium-
dependent and-independent mechanisms.
doi:10.1016/j.lfs.2013.12.145
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Endothelin-2 (ET-2) is highly expressed in the granulosa cells
(GCs) of periovulatory ovary. Previous experiments demonstrated
that endothelin receptor antagonization inhibits ovulation in ro-
dents. In the ovary ET-2 is expressed only in the GCs, while
endothelin receptors are expressed in a variety of ovarian cell types.
This study was designed to determine the signiﬁcance of the
expression of endothelin A receptor (ETA, a protein product of Ednra
gene) in the granulosa cells. Two lines of GC-speciﬁc Ednra knockout
mice were generated by crossbreeding Ednra-ﬂox/ﬂox mice with
either Amhr2Cre or Cyp19Cre mice which express Cre recombinase
under the anti-Mullerian hormone receptor promoter and the
aromatase promoter, respectively. While both transgenic mice
express Cre in the granulosa cells, the Cyp19Cre mouse were
expected to have a higher rate of Ednra deletion than the Amhr2Cre
mouse. Reproductive function of the resulting mice was measured by
their fertility and litter size (number of pups per mouse and pups per
litter) after breeding the GC-speciﬁc Ednra knockout female mice
with proven males. Ednra deletion driven by either Amhr2Cre mice
(GC-EdnraKO-amhr2) or Cyp19Cre mice (GC-EdnraKO-Cyp19) re-
duced fertility (57.9% in GC-EdnraKO-Amhr2 and 42.3% in GC-
EdnraKO-Cyp19 compared to 76.5% in WT, p = 0.22 and p = 0.02,
respectively). In addition, GC-EdnraKO-Amhr2 and GC-EdnraKO-
Cyp19 mice had signiﬁcantly smaller litter size as well (3.55 ± 0.45
and 4.56 ± 0.53 vs 7.08 ± 0.48 in WT, p b 0.01 for each). Taken
together, this study demonstrates that ETA in granulosa cells plays
an important role for female fertility in mice.
doi:10.1016/j.lfs.2013.12.146
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Long-lasting arterial contractions induced by endothelin-1 (ET-1) are
caused by tight binding of ET-1 to ETA receptors. Slow dissociation of ET-
1 from ETA receptors suggests that i) an endogenous system effectively
counteracts an otherwise continuously active contractile system and ii)
inhibitors of contractile mechanisms or stimuli of relaxing mechanisms
must induce long-lasting effects in order to effectively counteract the ET
system. In isolated rat mesenteric resistance arteries, we studied these
potentially effective pharmacological approaches. Calcitonin gene-
related peptide (CGRP) only slightly reduced arterial sensitivity to ET-1
but terminated ET-1-induced vasospasms by promoting dissociation of
ET-1/ETA receptor complexes. The CGRP effects were mediated by CGRP
receptors and not mimicked by stimuli of mediators downstream of
Gαs-proteins such as adenylate cyclase (AC), but rather were blocked by
Gβγ- inhibition. Stimuli of AC such as forskolin and isoproterenol did
produce a readily reversible relaxation of ET-1-induced vasospasms
without affecting the initial contractions. The poorly reversible stimula-
tor (Bay412272) and activator (Bay602770) of soluble guanylate cyclase
produced long-lasting relaxations, also without inhibiting the initial ET-
1-induced contractions. Rho-kinase inhibition (OH- fasudil)waswithout
effect, TRPC3 or L-VOCC inhibition (Pyr3 and felodipine, respectively)
only relaxed ET-1-induced vasospasms and PLC inhibition (U73122)
strongly reduced contractile responses to ET-1 and relaxed the
vasospasms. These results suggest that long-acting physiological and
functional antagonists can effectively relax ET-1-induced vasospasms.
Therefore, these systems can provide an alternative for current ETA
antagonists which do not display this beneﬁcial characteristic. This study
was performed within the framework of TI Pharma projects T2-301 and
T2-108.
doi:10.1016/j.lfs.2013.12.147
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Inhibition of resistance artery responses to endothelins (ETs) might
be useful in therapy-resistant hypertension and stroke. ETs cause long-
lasting arterial contractions by tight binding to smooth muscle ETA
receptors. Chemically diverse ET-receptor antagonists (ERA) inhibit
binding of ET-1 to ETA and reduce sensitivity to ETs. We investigated
negative allosteric modulation by ERA in isolated rat resistance arteries.
1 μM BQ123 (cyclic pentapeptide) reversibly relaxed contractile
responses to 32 nM ET-1 to a different extent in arteries from different
vascular beds (−0 to −80%) and reduced mesenteric artery (MA)
sensitivity to ET-1 more avidly (pKB 7.6 ±0.4) than that to ET-2 (pKB
5.6 ± 0.4). This agonist-dependence was less marked with 100 nM PD-
156707 (butenolide; pKB 8.5 ± 0.3 and 7.9 ± 0.3) and not signiﬁcant
with 1 nM BMS-193884 (biphenyl sulphonamide; pKB 9.3 ± 0.1 and
9.2 ± 0.1). Effects of high concentrations of BMS-193884 on MA
sensitivity to ET-1 and ET-2 were not concentration-dependent. In the
presence of 10 nMBMS-193884, i) 1 μMBQ123 had no additional effect
but ii) 100 nM PD-156707 resulted in a further signiﬁcant reduction of
MA sensitivity to ET-1. Binding i) a ﬂuorophore to PD-156707 (useful
for diagnosis) or ii) an angiotensin AT1-antagonistic moiety to BMS-
193884 (dual antagonist PS-433540) impaired ET-antagonism by the
pharmacophores. Thus, chemically distinct ERA act differently on
resting and agonist-activated ETA receptors and display system- and
agonist-dependence and saturability (pharmacological properties of
allosteric modulation). Also, the observations suggest the presence of
several allosteric binding sites on ETA receptors, the structure-activity
relationships of which can be studied.
doi:10.1016/j.lfs.2013.12.148
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Extracellular superoxide dismutase (EC-SOD), one member of SOD
family, exists outside the cells in mammals. It catalyzes conversion of
superoxide anion (O2−) into hydrogen peroxide (H2O2), destroying
free radicals upon reactive oxygen species (ROS) production to relieve
oxidative stress. In this study, a methylotrophic Pichia pastoris system
was used to produce a large-scale of recombinant human EC-SOD by
yeast fermentation. After puriﬁed by fast protein liquid chromatogra-
phy (FPLC), three different subtypes of EC-SOD were performed.
Furthermore, the spontaneously hypertensive rat (SHR) was used to
examine anti-hypertension efﬁciency among different EC-SOD isoforms
through blood pressure measurement and NO release in blood after tail
intravenous injection of EC-SOD. Results showed that different subtypes
of EC-SOD share similar secondary structure but their activity diverse.
After injection of high-dose EC-SOD into SHR, we observed obvious
decrease of blood pressure and increase of blood nitric oxide (NO)
immediately. After blocking the NO synthesis, EC-SOD lost its ability of
blood pressure regulation. Our data provided that enormous antioxi-
dant and antihypertensive activities of human EC-SOD were largely
produced by yeast fermentation. It can be applied on the extent of
health care to prevent hypertension and also cardiovascular diseases.
doi:10.1016/j.lfs.2013.12.149
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The fermented milk has antithrombotic, immunomodulatory,
antihypertensive and cardiovascular effects. In the present study,
the fermented milk and its derived peptide, 19AA, were investigated
for the ﬁrst time. Results demonstrated that the fermented milk had
a strong antihypertensive activity in spontaneous hypertension rats
(SHRs). Among two fractions derived from the fermented milk,
Fraction A exhibited the best antihypertensive activity. Following
reverse-phase high-performance liquid chromatography, a 19AA
short peptide was further puriﬁed and identiﬁed from Fraction A.
The synthetic peptide with a sequence of 19AA showed the strong
antihypertensive activity from 1 to 10 h after oral administration of
1 mg of 19AA/kg of body weight, and the effect of systolic and
diastolic blood pressure (SBP and DBP) decreasing was maximal at
44.0 ± 2.1 mmHg and 23.0 ± 2.9 mmHg, respectively, after oral
administration. The present study revealed that 19AA showed
excellent antihypertensive activity, and its activity is better than
that of VPP tripeptide which has been already included in functional
foods. In conclusion, the 19AA fermented peptide is the bioactive
ingredient with potential beneﬁt in the prevention and treatment of
hypertension or other associated disorders.
doi:10.1016/j.lfs.2013.12.150
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Background: ET-1 levels rise in PAH, correlating with increased
pulmonary vascular resistance and mortality. Lung endothelial ETB
receptors promote ET-1 clearance, which is improved in PAH
patients by epoprostenol (prostacyclin). Whether prostacyclin
analogues behaviour similarly is unclear or if smooth muscle ETB
receptors regulate ET-1 levels. Methods: Cultured human PASMCs
from PAH patients were treated for 24 h with treprostinil, an ETRA or
a combination. A chemiluminescent ELISA was used to measure ET-1
in the supernatant while ET-1 converting enzyme (ECE-1) and ETB
expression were evaluated by Westerns and immunohistochemistry
in lung sections. Results: Serum doubled ET-1 levels in HPSMCs, an
effect abolished by treprostinil (10–100 nM). In contrast, the ERTAs
(100 nM) bosentan and ambrisentan increased ET-1 levels by 100%
while BQ788 (selective ETB antagonist) by 200%. Treprostinil in
combination with these ETRAs failed to inhibit serum-induced ET-1
elevation. In contrast, BQ123 (selective ETA antagonist) did not affect
the response to serum or treprostinil. ECE-1 protein levels were
higher with BQ788 and bosentan compared to serum or treprostinil.
Furthermore, ETB expression was down-regulated by all ETRAs, but
not by treprostinil. In the smooth muscle layer of PAH lungs,
ECE-1 and ETB expression was markedly increased. Conclusion:
Treprostinil potently inhibits ET-1 levels in human PASMCs which
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